Literature DB >> 28580145

Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.

Yinjian Zhou1,2, Ying Dong3, Gang Huang2, Yiguang Wang2, Xiaonan Huang2, Fayun Zhang1, David A Boothman3, Jinming Gao2, Wei Liang1.   

Abstract

β-Lapachone (β-n class="Gene">lap), a novel anticancer agent, is bioactivated by NADP(H):quinone oxidoreductase 1 (NQO1), an enzyme over-expressed in numerous tumors, including lung, pancreas, breast, and prostate cancers. Fast renal clearance and methemaglobinemia / hemolytic side-effects from the clinical formulation (β-lap-hydroxyl propyl-β-cyclodextrin complex) hindered its clinical translation. Here, we investigated a dual model pH responsive polymers for β-lap delivery. Three pH-sensitive linkages, including acylhydrazone, ketal and imine bonds for β-lap prodrug syntheses result in an aryl imine linkage the most optimal linkage. The conversion to β-lap was 2.8%, 4.5% and 100% at pH 7.4, 6.5 and 5.0 in 8 h, respectively. β-lap aryl imine prodrug conjugated ultra pH-sensitive (UPS) polymer reached high β-lap loading density (8.3%) and exhibited dual-stages responsiveness to pH variation. In pHs under pHt, at stage I, micelle immediately dissociation and subsequently entering stage II, micelles start quickly release β-lap. In vitro release study showed that the micelles constantly release β-lap (14.9 ± 0.1%) at pHs above pHt in 72 h, whereas boosted release of β-lap (79.4 ± 1.2%) at pH 5.0. Micelle intracellular distribution predominantly in the lysosome organelle guaranteed their pH responsive dissociation and subsequently β-lap controlled release. The M-P micelles retained NQO1-dependent cytotoxicity in A549 lung cancer cells, similar to free drug in both efficacy and mechanism of cell death. The lysosome-oriented dual-stage ultra pH responsive β-lap prodrug micelles potentially offer an alternative nanotherapeutic strategy for lung, as well as other NQO1+ cancer therapies.

Entities:  

Keywords:  Ultra pH-sensitive; drug release; prodrug micelles; staged pH responsive; β-Lapachone (β-lap)

Year:  2016        PMID: 28580145      PMCID: PMC5452003          DOI: 10.1039/C6TB02049F

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  40 in total

Review 1.  Lysosomal acidification mechanisms.

Authors:  Joseph A Mindell
Journal:  Annu Rev Physiol       Date:  2012       Impact factor: 19.318

2.  Spacer optimization of new conjugates for a melanoma-selective delivery approach.

Authors:  Mathieu André; Sébastien Tarrit; Marie-Joelle Couret; Marie-Josèphe Galmier; Eric Débiton; Jean-Michel Chezal; Emmanuelle Mounetou
Journal:  Org Biomol Chem       Date:  2013-10-07       Impact factor: 3.876

Review 3.  Stimuli-responsive polymers: biomedical applications and challenges for clinical translation.

Authors:  Allan S Hoffman
Journal:  Adv Drug Deliv Rev       Date:  2012-12-12       Impact factor: 15.470

4.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration.

Authors:  Hong-Jun Li; Jin-Zhi Du; Jing Liu; Xiao-Jiao Du; Song Shen; Yan-Hua Zhu; Xiaoyan Wang; Xiaodong Ye; Shuming Nie; Jun Wang
Journal:  ACS Nano       Date:  2016-06-03       Impact factor: 15.881

5.  Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system.

Authors:  Aaron P Griset; Joseph Walpole; Rong Liu; Ann Gaffey; Yolonda L Colson; Mark W Grinstaff
Journal:  J Am Chem Soc       Date:  2009-02-25       Impact factor: 15.419

6.  A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals.

Authors:  Yiguang Wang; Kejin Zhou; Gang Huang; Christopher Hensley; Xiaonan Huang; Xinpeng Ma; Tian Zhao; Baran D Sumer; Ralph J DeBerardinis; Jinming Gao
Journal:  Nat Mater       Date:  2013-12-08       Impact factor: 43.841

7.  Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.

Authors:  Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Erik A Bey; David A Boothman
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 13.312

8.  An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Authors:  Erik A Bey; Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Chin-Rang Yang; Luc Girard; John D Minna; William G Bornmann; Jinming Gao; David A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 12.779

9.  Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.

Authors:  Norased Nasongkla; Andy F Wiedmann; Andrew Bruening; Meghan Beman; Dale Ray; William G Bornmann; David A Boothman; Jinming Gao
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.580

10.  Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.

Authors:  Lifen Cao; Long Shan Li; Christopher Spruell; Ling Xiao; Gaurab Chakrabarti; Erik A Bey; Kathryn E Reinicke; Melissa C Srougi; Zachary Moore; Ying Dong; Peggy Vo; Wareef Kabbani; Chin-Rang Yang; Xiaoyu Wang; Farjana Fattah; Julio C Morales; Edward A Motea; William G Bornmann; John S Yordy; David A Boothman
Journal:  Antioxid Redox Signal       Date:  2014-04-03       Impact factor: 7.468

View more
  1 in total

1.  Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.

Authors:  Claudio D Navo; Julie Becher; Enrique Gil de Montes; Ana Guerreiro; Lavinia Dunsmore; Emily Hoyt; Libby Brown; Viviane Zelenay; Sigitas Mikutis; Jonathan Cooper; Isaia Barbieri; Stefanie Lawrinowitz; Elise Siouve; Esther Martin; Pedro R Ruivo; Tiago Rodrigues; Filipa P da Cruz; Oliver Werz; George Vassiliou; Peter Ravn; Gonzalo Jiménez-Osés; Gonçalo J L Bernardes
Journal:  Nat Chem       Date:  2022-06-27       Impact factor: 24.274

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.